Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.15 EUR | 16.67% |
| 2022 | -0.18 EUR | -167.46% |
| 2021 | -0.07 EUR | -551.68% |
| 2020 | 0.01 EUR | 102.71% |
| 2019 | -0.55 EUR | -205.56% |
| 2018 | -0.18 EUR | 84.48% |
| 2017 | -1.16 EUR | -141.67% |
| 2016 | -0.48 EUR | 0.0% |
| 2015 | -0.48 EUR | -152.63% |
| 2014 | -0.19 EUR | 74.32% |
| 2013 | -0.74 EUR | -13.85% |
| 2012 | -0.65 EUR | 20.73% |
| 2011 | -0.82 EUR | -510.0% |
| 2010 | 0.20 EUR | 117.54% |
| 2009 | -1.14 EUR | 28.3% |
| 2008 | -1.59 EUR | -13.57% |
| 2007 | -1.40 EUR | 3.45% |
| 2006 | -1.45 EUR | -62.92% |
| 2005 | -0.89 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.03 EUR | -18.44% |
| 2024 Q2 | -0.03 EUR | 0.0% |
| 2023 Q2 | -0.10 EUR | -99.6% |
| 2023 Q3 | -0.03 EUR | 71.8% |
| 2023 Q4 | -0.03 EUR | 0.0% |
| 2023 FY | - EUR | 16.67% |
| 2023 Q1 | -0.05 EUR | 31.28% |
| 2022 FY | - EUR | -167.46% |
| 2022 Q2 | -0.11 EUR | -93.66% |
| 2022 Q3 | -0.04 EUR | 66.73% |
| 2022 Q4 | -0.07 EUR | -99.18% |
| 2022 Q1 | -0.06 EUR | -347.24% |
| 2021 Q2 | -0.06 EUR | -88.33% |
| 2021 Q4 | -0.01 EUR | -101.59% |
| 2021 FY | - EUR | -551.68% |
| 2021 Q1 | -0.03 EUR | 40.36% |
| 2021 Q3 | -0.01 EUR | 88.85% |
| 2020 FY | - EUR | 102.71% |
| 2020 Q3 | -0.03 EUR | -145.24% |
| 2020 Q4 | -0.05 EUR | -73.45% |
| 2020 Q2 | 0.06 EUR | 70.03% |
| 2020 Q1 | 0.04 EUR | 109.2% |
| 2019 Q3 | -0.19 EUR | -26.67% |
| 2019 Q4 | -0.41 EUR | -115.79% |
| 2019 Q2 | -0.15 EUR | -96.08% |
| 2019 FY | - EUR | -205.56% |
| 2019 Q1 | -0.08 EUR | -779.31% |
| 2018 Q1 | -0.09 EUR | 81.45% |
| 2018 FY | - EUR | 84.48% |
| 2018 Q4 | -0.01 EUR | 0.0% |
| 2018 Q3 | -0.01 EUR | 89.76% |
| 2018 Q2 | -0.08 EUR | 2.52% |
| 2017 Q4 | -0.47 EUR | 0.0% |
| 2017 FY | - EUR | -141.67% |
| 2017 Q1 | -0.12 EUR | -9.09% |
| 2017 Q2 | -0.12 EUR | 0.0% |
| 2017 Q3 | -0.47 EUR | -291.67% |
| 2016 Q3 | -0.11 EUR | 21.43% |
| 2016 FY | - EUR | 0.0% |
| 2016 Q1 | -0.14 EUR | -40.0% |
| 2016 Q2 | -0.14 EUR | 0.0% |
| 2016 Q4 | -0.11 EUR | 0.0% |
| 2015 Q1 | -0.14 EUR | -367.18% |
| 2015 Q2 | -0.14 EUR | 0.0% |
| 2015 FY | - EUR | -152.63% |
| 2015 Q4 | -0.10 EUR | 0.0% |
| 2015 Q3 | -0.10 EUR | 28.57% |
| 2014 Q1 | -0.21 EUR | -23.53% |
| 2014 FY | - EUR | 74.32% |
| 2014 Q3 | 0.05 EUR | 124.95% |
| 2014 Q2 | -0.21 EUR | 0.0% |
| 2014 Q4 | 0.05 EUR | 0.0% |
| 2013 FY | - EUR | -13.85% |
| 2013 Q2 | -0.21 EUR | 0.0% |
| 2013 Q1 | -0.21 EUR | 0.0% |
| 2013 Q3 | -0.17 EUR | 19.05% |
| 2013 Q4 | -0.17 EUR | 0.0% |
| 2012 FY | - EUR | 20.73% |
| 2011 FY | - EUR | -510.0% |
| 2010 FY | - EUR | 117.54% |
| 2009 FY | - EUR | 28.3% |
| 2008 FY | - EUR | -13.57% |
| 2007 FY | - EUR | 3.45% |
| 2006 FY | - EUR | -62.92% |
| 2005 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ABIONYX Pharma SA | -0.12 EUR | -25.0% |
| ABIVAX Société Anonyme | -3.43 EUR | 95.627% |
| Adocia SA | -1.91 EUR | 92.147% |
| Aelis Farma SA | -0.39 EUR | 61.538% |
| Biophytis S.A. | -12.55 EUR | 98.805% |
| Advicenne S.A. | -0.67 EUR | 77.612% |
| genOway Société anonyme | 0.17 EUR | 188.235% |
| IntegraGen SA | -0.03 EUR | -479.151% |
| Medesis Pharma S.A. | -0.80 EUR | 81.25% |
| Neovacs S.A. | -0.00 EUR | -5900.0% |
| NFL Biosciences SA | -0.46 EUR | 67.391% |
| Plant Advanced Technologies SA | 0.07 EUR | 314.286% |
| Quantum Genomics Société Anonyme | -0.09 EUR | -64.835% |
| Sensorion SA | -0.17 EUR | 11.765% |
| Theranexus Société Anonyme | -0.88 EUR | 82.955% |
| TME Pharma N.V. | -1.34 EUR | 88.806% |
| Valbiotis SA | -0.59 EUR | 74.576% |
| TheraVet SA | -0.49 EUR | 69.388% |
| argenx SE | -4.67 EUR | 96.788% |
| BioSenic S.A. | -0.21 EUR | 28.571% |
| Celyad Oncology SA | -0.33 EUR | 54.545% |
| DBV Technologies S.A. | -0.71 EUR | 78.873% |
| Galapagos NV | 3.21 EUR | 104.673% |
| Genfit S.A. | -0.58 EUR | 74.138% |
| GeNeuro SA | -0.59 EUR | 74.576% |
| Hyloris Pharmaceuticals SA | -0.55 EUR | 72.727% |
| Innate Pharma S.A. | -0.09 EUR | -59.405% |
| Inventiva S.A. | -2.43 EUR | 93.827% |
| MaaT Pharma SA | -1.73 EUR | 91.329% |
| MedinCell S.A. | -0.88 EUR | 82.955% |
| Nanobiotix S.A. | -1.08 EUR | 86.111% |
| Onward Medical N.V. | -1.20 EUR | 87.5% |
| Oryzon Genomics S.A. | -0.06 EUR | -172.232% |
| OSE Immunotherapeutics SA | -1.18 EUR | 87.288% |
| Oxurion NV | -0.01 EUR | -1204.348% |
| Pharming Group N.V. | -0.01 EUR | -934.483% |
| Poxel S.A. | -0.91 EUR | 83.516% |
| GenSight Biologics S.A. | -0.54 EUR | 72.222% |
| Transgene SA | -0.22 EUR | 31.818% |
| Financière de Tubize SA | 1.98 EUR | 107.576% |
| UCB SA | 1.81 EUR | 108.287% |
| Valneva SE | -0.73 EUR | 79.452% |
| Vivoryon Therapeutics N.V. | -1.12 EUR | 86.607% |